Skip to main content

Advertisement

Table 8 One-way sensitivity analysis results for genotype 2/3 comparing peginterferon-alfa-2a to peginterferon-alfa-2b

From: Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil

Parameter Lower parameter value Higher parameter value Result
Cost difference LY difference QALY difference Cost difference LY difference QALY difference
Utility values1 -$Brz 4345 0,10 0,34 -$Brz 4345 0,10 0,17 Dominant
Medical costs1 -$Brz 4098 0,10 0,26 -$Brz 4592 0,10 0,26 Dominant
State-transition probabilities1 -$Brz 4250 0,08 0,22 -$Brz 4411 0,13 0,27 Dominant
Peginterferon-alfa-2a acquisition cost1 -$Brz 5314 0,10 0,26 -$Brz 3376 0,10 0,26 Dominant
Peginterferon-alfa-2b acquisition cost1 -$Brz 2972 0,10 0,26 -$Brz 5718 0,10 0,26 Dominant
Patient weight2 -$Brz 1729 0,10 0,26 -$Brz 6961 0,10 0,26 Dominant
SVR3 -$Brz 3576 0,05 0,14 -$Brz 5114 0,15 0,38 Dominant
Starting age4 -$Brz 4459 0,13 0,29 -$Brz 4927 0,09 0,22 Dominant
  1. Notes: 1Parameters were varied over the range of ±15%; 2Parameter was varied from 50 to 90 kg; 3Parameter was varied according to lower and upper limit values obtained from meta-analysis; 4Parameter was varied from 40 to 50 years old.